{"resourceType":"ClinicalUseDefinition","id":"example-undesirable","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"undesirable-effect","subject":[{"reference":{"reference":"MedicinalProductDefinition/example"}}],"undesirableEffect":{"symptomConditionEffect":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/undesirableeffectassymptom-condition-effect","code":"Anaemia"}]}},"classification":{"coding":[{"system":"http://ema.europa.eu/example/symptom-condition-effectclassification","code":"Blood-and-lymphatic-system-disorders"}]},"frequencyOfOccurrence":{"coding":[{"system":"http://ema.europa.eu/example/frequencyofoccurrence","code":"Common"}]}}}
{"resourceType":"ClinicalUseDefinition","id":"example-warning","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"warning","category":[{"coding":[{"system":"http://hl7.org/fhir/clinical-use-definition-category","code":"DriveAndMachines","display":"Effects on Ability to Drive and Use Machines"}]}],"subject":[{"reference":{"reference":"MedicinalProductDefinition/example"}}],"warning":{"description":"May cause drowsiness. Avoid driving or operating heavy machinery."}}
{"resourceType":"ClinicalUseDefinition","id":"example-indication","contained":[{"resourceType":"Group","id":"group","type":"person","membership":"definitional","characteristic":[{"code":{"coding":[{"system":"http://ema.europa.eu/example/characteristic","code":"age-range"}]},"valueRange":{"low":{"value":18,"unit":"a"}},"exclude":false}]}],"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"indication","subject":[{"reference":{"reference":"MedicinalProductDefinition/example"}}],"indication":{"diseaseSymptomProcedure":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/indicationasdisease-symptom-procedure","code":"Pulmonary-embolism-and-thrombosis-example-code"}],"text":"Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."}},"diseaseStatus":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/diseasestatus","code":"Recurrent"}]}},"intendedEffect":[{"concept":{"coding":[{"system":"http://ema.europa.eu/example/intendedeffect","code":"PRYLX"}]}}]},"population":[{"reference":"#group"}]}
{"resourceType":"ClinicalUseDefinition","id":"example-interaction","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"interaction","subject":[{"reference":{"reference":"MedicinalProductDefinition/example"}}],"interaction":{"interactant":[{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"alphaconazole"}]}},{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"betaconazole"}]}}],"type":{"coding":[{"system":"http://ema.europa.eu/example/interactionsType","code":"Inhibitor"}]},"effect":{"concept":{"text":"Increased plasma concentration"}},"management":[{"text":"Careful monitoring of dose"}]}}
{"resourceType":"ClinicalUseDefinition","id":"example-contraindication","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"contraindication","subject":[{"reference":{"reference":"MedicinalProductDefinition/example"}}],"contraindication":{"diseaseSymptomProcedure":{"concept":{"text":"Concomitant treatment with any other anticoagulant agent"}},"indication":[{"diseaseSymptomProcedure":{"concept":{"text":"Stroke"}}}],"otherTherapy":[{"relationshipType":{"coding":[{"system":"http://ema.europa.eu/example/therapyrelationshiptype","code":"Co-therapy(with)"}]},"treatment":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/medication","code":"Oralanticoagulants"}]}}},{"relationshipType":{"coding":[{"system":"http://ema.europa.eu/example/therapyrelationshiptype","code":"Co-therapy(with)"}]},"treatment":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/medication","code":"Lowmolecularweightheparins"}]}}}]}}
{"resourceType":"ClinicalUseDefinition","id":"example","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"contraindication","subject":[{}],"contraindication":{"diseaseSymptomProcedure":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/contraindicationsasdisease-symptom-procedure","code":"hepatic-example-code"}],"text":"Hepatic disease associated with coagulopathy and clinically relevant bleeding risk"}}}}